Tesaro Inc. (NASDAQ:TSRO) traded up 3.7% on Thursday . The stock traded as high as $94.19 and last traded at $93.51, with a volume of 379,522 shares traded. The stock had previously closed at $90.18.

A number of brokerages recently commented on TSRO. Credit Suisse Group AG restated a “buy” rating on shares of Tesaro in a report on Saturday, May 14th. Jefferies Group restated a “buy” rating on shares of Tesaro in a report on Sunday, May 8th. Citigroup Inc. raised their price objective on shares of Tesaro from $90.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, August 8th. Leerink Swann restated a “buy” rating on shares of Tesaro in a report on Monday, June 6th. Finally, FBR & Co restated a “buy” rating and set a $65.00 price objective on shares of Tesaro in a report on Friday, May 6th. Two analysts have rated the stock with a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $85.50.

The firm’s 50-day moving average price is $85.89 and its 200-day moving average price is $53.07. The firm’s market capitalization is $4.95 billion.

Tesaro (NASDAQ:TSRO) last released its quarterly earnings results on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share for the quarter, beating the consensus estimate of ($1.71) by $0.43. The company earned $36.60 million during the quarter, compared to the consensus estimate of $4.98 million. During the same quarter last year, the firm earned ($1.51) EPS. On average, analysts forecast that Tesaro Inc. will post ($7.29) EPS for the current year.

In related news, VP Edward C. English sold 7,000 shares of Tesaro stock in a transaction on Friday, June 10th. The shares were sold at an average price of $40.75, for a total value of $285,250.00. Following the sale, the vice president now owns 3,500 shares in the company, valued at $142,625. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, VP Jeffrey H. Hanke sold 12,500 shares of Tesaro stock in a transaction on Thursday, June 30th. The shares were sold at an average price of $74.35, for a total transaction of $929,375.00. Following the completion of the sale, the vice president now owns 12,500 shares in the company, valued at approximately $929,375. The disclosure for this sale can be found here.

A number of hedge funds recently added to or reduced their stakes in TSRO. Rhumbline Advisers boosted its stake in Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock valued at $1,172,000 after buying an additional 1,915 shares during the period. Bank of Montreal Can boosted its stake in Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock valued at $1,275,000 after buying an additional 24,119 shares during the period. Nationwide Fund Advisors boosted its stake in Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock valued at $1,394,000 after buying an additional 330 shares during the period. Mutual of America Capital Management LLC boosted its stake in Tesaro by 95.6% in the fourth quarter. Mutual of America Capital Management LLC now owns 39,520 shares of the biopharmaceutical company’s stock valued at $2,068,000 after buying an additional 19,320 shares during the period. Finally, Jennison Associates LLC boosted its stake in Tesaro by 157.5% in the fourth quarter. Jennison Associates LLC now owns 938,461 shares of the biopharmaceutical company’s stock valued at $49,100,000 after buying an additional 574,041 shares during the period.

TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.